London, April 23 (IANS) Two scientists who are leading the charge for a vaccine in the UK have been speaking about their projects.
Professor Sarah Gilbert is head of a team at the University of Oxford. Trials, which have had 5,000 volunteers, are set to begin on Thursday, the BBC reported.
"We just start with two people on the first day, to make sure that everything is well with them, and also that all the procedures are working for the trial and that we are ready to move on to larger numbers."
Professor Robin Shattock, who leads Imperial College London's effort, said if either project provides the "right signal in terms of safety and efficacy", a vaccine could be available for the UK's front-line workers and the most vulnerable before the end of the year.
But he said it would be next year before it could be rolled out around the world.
However, Chief Medical Officer, Professor Chris Whitty, said that the development of a "highly effective" vaccine or drug could be the only solution but he warned one was unlikely to arrive in the next calendar year, but an antibody test - could be available in the "pretty near future"
--IANS
rt/
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!